Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$15.11B+1023.61%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Francesco Milleri
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 203,791
- Beta
- 0.55
- Country
- FR
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.23
Financials
Revenue
$15.11B+1023.6%Net Income
$1.60B+955.4%EBITDA
$3.92B+1471.3%Free Cash Flow
$1.55B+1160.4%EPS (diluted)
$1.72+391.4%Shares Outstanding (diluted)
928.86M+114.7%Operating Expenses
$7.00BCash & Debt
$1.93BReturn of Capital
$2.67BDividend per Share
$2.32Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $28.49B | $2.22B | $2.42 |
| 2024 | $26.51B | $2.36B | $2.60 |
| 2023 | $25.39B | $2.29B | $2.56 |
| 2022 | $24.49B | $2.15B | $2.44 |
| 2021 | $19.82B | $1.45B | $1.65 |
| 2020 | $14.43B | $85.00M | $0.10 |
| 2019 | $17.39B | $1.08B | $1.24 |
| 2018 | $10.83B | $1.08B | $2.08 |
| 2017 | $9.18B | $789.00M | $1.79 |
| 2016 | $7.12B | $813.00M | $1.90 |
| 2015 | $6.72B | $757.00M | $1.79 |
| 2014 | $5.67B | $929.00M | $2.21 |
| 2013 | $5.07B | $593.00M | $1.41 |
| 2012 | $4.99B | $584.00M | $1.40 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ESLOY's reported EPS growth of 4.3% a year over 13 years.
- EPS in 5 years
- $2.99
- Implied price
- $167.42
- Return from $90.05
- 13.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $83.24 — -7.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 40 | 48 | 56 | 64 | 72 |
|---|---|---|---|---|---|
| -5.7% | -4.3% | -0.8% | 2.4% | 5.1% | 7.6% |
| -0.7% | 0.8% | 4.5% | 7.8% | 10.7% | 13.3% |
| 4.3% | 5.8% | 9.8% | 13.2% | 16.3% | 19.0% |
| 9.3% | 10.9% | 15.0% | 18.6% | 21.8% | 24.7% |
| 14.3% | 16.0% | 20.3% | 24.1% | 27.4% | 30.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
143+186.67%Social Signal Score
Mentions (4)
- Newswsj.com·6h ago·Negative
Ray-Ban Maker EssilorLuxottica's Sales Rise, Buoyed by Smartglasses Sales of smartglasses, powered by artificial intelligence and produced in partnership with tech giant Meta, jumped 20% in the third quarter.
View source ↗ - Newsreuters.com·7h ago·Neutral
EssilorLuxottica tops estimates in Q3 despite slowdown in growth of smart glasses EssilorLuxottica tops estimates in Q3 despite slowdown in growth of smart glasses
View source ↗ - Newsreuters.com·14h ago·Neutral
EssilorLuxottica's smart glasses boom runs into tougher regulatory scrutiny EssilorLuxottica's smart glasses boom runs into tougher regulatory scrutiny
View source ↗ - Newsseekingalpha.com·20d ago·Neutral
EssilorLuxottica: Governance Noise, Smart-Glasses Upside, And Armani Optionality Delfin's internal dispute has not disrupted operations, while EssilorLuxottica's board has reaffirmed full support for Francesco Milleri and current management. Smart glasses are increasingly becoming a separate growth engine, supported by broader distribution, new products, higher adoption, and an expanding ecosystem around lenses and AI-enabled functionality. Armani could represent an additional strategic opportun
View source ↗
Earnings
Wed, Feb 17(in 4 months)
Consensus estimate $1.88 per share
Typical surprise +0.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$1.92 vs $2.22miss
- Wed, Feb 11$1.73 vs $1.57beat
- Mon, Jul 28$1.73 vs $2.29miss
- Wed, Feb 12$1.55 vs $1.45beat
- Thu, Jul 25$1.62 vs $1.99miss
- Wed, Feb 14$1.53 vs $1.52beat
Estimates and results for ESLOY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$100,001 - $250,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Sell$1,001 - $15,000
- Mikie Sherrillhouse · NJ11 · disclosed Jul 8, 2019 (41d later)Sell$1,001 - $15,000
- Shelley Moore Capitosenate · WV · disclosed Apr 17, 2019 (37d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.